Objective: To compare cost and efficacy of tubal anastomosis to in vitro fertilization (IVF) Result(s): Cost per ongoing pregnancy for women after tubal anastomosis ranged from $16,446 to $223,482 (2014 USD), whereas IVF ranged from $32,902 to $111,679 (2014 USD). Across maternal age groups <35 and 35-40, years tubal anastomosis was more cost effective than IVF for ongoing pregnancy. Sensitivity analyses validated these findings across a wide range of ongoing pregnancy probabilities as well as costs per procedure. Conclusion(s): Tubal anastomosis was the most cost-effective approach for most women less than 41 years of age, whereas IVF was the most cost-effective approach for women aged R41 years who desired fertility after tubal ligation. A model was created that can be modified based on cost and success rates in individual clinics for improved patient counseling.
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F emale sterilization is one of the most commonly chosen contraceptive methods worldwide. More than 30% of couples in the United States elect to undergo surgical sterilization (1) . There are more than 650,000 tubal ligations performed each year in the United States and up to 30% will come to regret the decision with 1% ultimately seeking reversal (2) (3) (4) . The most common reasons cited for seeking anastomosis after tubal ligation are a change in marital status and desire for more children (2, 3) . Given the high divorce rate in the United States, it is likely that thousands of women will seek restoration of their fertility after undergoing tubal ligation. At present, the only options for additional children are in vitro fertilization (IVF) or surgical tubal anastomosis (TA). An American Society for Reproductive Medicine Committee Opinion supports TA as an option for post-tubal ligation fertility and, when considering options, reports age as the most important prognostic factor (4) . However, in spite of the reported success rates, TA is being performed less frequently, and taught less frequently in fellowship training programs in the United States. According to one US survey, 43% of fellows had not performed a TA as primary surgeon (5) . Among the reasons for this trend is the increasing success rate of IVF. Although IVF and TA success rates are globally similar, one procedure may have an advantage versus another for an individual patient, in terms of efficacy and cost. Because there is no clear-cut advantage of one procedure versus another, it would be useful to have information that would facilitate individualized counseling. Our goal was to identify an objective way to counsel patients regarding the two options, using cost and efficacy data stratified by age group. To meet this objective, we created a decision tree model, based on published data, to compare the overall cost to achieve an ongoing pregnancy between IVF and TA. This information may assist both patients and physicians in making the decision between IVF and TA.
MATERIALS AND METHODS
We generated a decision tree model ( Fig. 1) to compare cost and efficacy of TA with IVF and the expected outcome of an ongoing pregnancy using data obtained from published literature and public resources from a societal perspective. We defined an ongoing pregnancy as one that is beyond 20 weeks, which was assumed to result in a live birth, and included known live birth rates when available. Because all values used in this evaluation were collected from publicly available data or previously published results, the study was judged exempt from Institutional Review Board approval.
The model began with a decision to proceed with a TA or a single cycle of IVF. For each event node that followed in the TA arm, probabilities were calculated as means from published data (Supplemental Table 1 , available online) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The probability of completing a TA was calculated based on postprocedure patency rates documented in the literature (11, 15, 16) . For each event node that followed in the IVF arm, probabilities were taken from the Society for Assisted Reproductive Technologies (SART) data for 2012 for women with a diagnosis of tubal factor infertility (21) .
For both arms, TA and IVF, a pregnancy was considered to have three possible outcomes: ongoing pregnancy, spontaneous abortion, or ectopic pregnancy (EP). Pregnancy rates (PRs) were calculated as a weighted mean from available data stratified by maternal age <35, 35-40, and >40 years ( Table 1 ). The EP rates were calculated as a mean from those cited in the literature for each method, TA and IVF (6-20, 22, 23) . The EP rate was assumed to be consistent across all age groups. For the IVF arm, the spontaneous abortion rate was calculated based on data from SART (21) . For the TA arm, the spontaneous abortion rate was assumed to be equivalent to the age-associated rate in the literature (24) .
Because a single cycle of IVF often generates sufficient embryos for a frozen cycle, an additional branch was added to the decision tree in the IVF arm for cases that, after ET, did not result in an ongoing pregnancy. The probability of frozen transfer was calculated as the ratio of frozen cycles initiated to fresh cycles initiated as extrapolated from SART data, which reported the number of total cycles initiated and the number of frozen cycles initiated in the year 2012 (21) . The ongoing pregnancy rate after a frozen IVF cycle was estimated based on SART 2012 data for women with a diagnosis of tubal factor infertility (21) .
To determine the average cost per ongoing pregnancy, we first determined the market price charges for a TA, a single cycle fresh IVF, and a single cycle frozen IVF. As these services are primarily provided on a fee-for-service basis with minimal insurance coverage, we estimated costs based on patient charges. We used existing literature (16, 25) and individual clinic's websites (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) to inform the parameters of our analysis. Twelve clinics across the United States were reached by phone and provided the charge to patients for completion of a TA procedure. These were used to estimate the mean market price for a TA procedure. As these data were collected and reviewed in 2014, it was considered to be in 2014 US dollars (USD). All costs from the literature were converted to 2014 USD by using the US Department of Labor Bureau of Labor Statistics Inflation Calculator (44). The charges for TA typically included the initial consultation visit, surgeon, facility, anesthesia, procedure, recovery, postoperative care, and up to one night hospitalization. The charges for the TA represent an average of reported charges for all techniques including laparotomy, mini-laparotomy, laparoscopy, or a robotic procedure.
The charges for IVF included physician visits, ultrasound and laboratory evaluation, oocyte retrieval, intracytoplasmic sperm injection (ICSI), embryo transfer (ET), embryology fees, and all medications. Because 50% of patients with tubal factor used ICSI (21) , this cost is included in the overall IVF calculation. The charges for a frozen ET included the physician's visits, ultrasound evaluation, embryology fees, and embryo storage and transfer. These charges were included only for the percentage of women who make it to this arm of the analysis. The charges for fresh and frozen IVF cycles were based on phone calls to fertility clinics as well as the literature (25-27, 29, 32, 34, 36-38, 40, 43) , which was adjusted to 2014 USD as previously described (44).
The costs for managing an EP and spontaneous abortion were obtained from the literature (16, (45) (46) (47) (48) and adjusted to 2014 USD as previously described (44). These estimates are an average and included expectant, medical, and surgical management (Supplemental Table 2 , available online).
The average cost per ongoing pregnancy was then calculated for each age group, <35, 35-40, and >40 years, at the mean observed pregnancy rate (PR) in the literature. We then performed one-way sensitivity analyses over a range of probabilities of each procedure's success (ongoing pregnancy percentage was varied from 5%-100%) to evaluate the robustness of the model and the underlying assumptions. Sensitivity analyses were also performed across a range of costs. Specifically, the cost of a TA was held constant at the mean value of $8,685 (2014 USD) and the cost for IVF was varied from $3,000 to $50,000. A second analysis was performed in which the cost of IVF was held constant at the mean value of $13,970 (2014 USD) with the cost for TA being varied from $1,000 to $21,000.
Two additional analyses were performed with added decision nodes in each arm. In one model, a decision node was incorporated to include a hysterosalpingogram (HSG) for the TA patients who failed to achieve pregnancy by 6 months despite a completed procedure. Based on the literature (Supplemental Table 1 ), the PR by 6 months is 55%, indicating that as many as 45% of patients undergoing a TA will qualify for an HSG at 6 months with the associated costs estimated by current procedural terminology (CPT) code (49) . For the IVF
FIGURE 1
Decision tree model comparing tubal anastomosis (TA) versus IVF for women after tubal ligation (for probabilities, see Table 1 ). 
Note: TA ¼ tubal anastomosis; NA ¼ not available. a-l Indicates corresponding decision node in Figure 1 .
arm, a decision node was added for patients who completed an ET to account for a rare, but serious, complication of IVF, ovarian hyperstimulation syndrome (OHSS). Despite the low frequency of occurrence, 1%-3% of cycles (50, 51) , it can be serious and increase costs significantly. The excess charges to diagnose and treat OHSS have been previously evaluated with an overall average cost per patient of $6,574 (52, 53) . The decision tree model for this data is not shown. In a second model, contraception was incorporated into the cost of the TA arm for those women who achieve a pregnancy. The use and cost of contraceptive services varies widely based on method and has been recently reviewed and reported by Trussell et al. (54) . For the purposes of the model, we assumed that 15% of women would choose repeat sterilization, 18% short-acting contraceptive methods, and 9% long-acting methods, whereas 57% would use natural family planning, male sterility, and/or condoms (54) . Average per year cost for the model was calculated as a weighted mean using the percent usage and cost for each method per year as reported in the literature (54, 55) . Women were assumed to need contraception from the age of the surgical procedure, average 34 years, until the age of menopause, which in the United States is an average of 52 years of age (1). This cost was incorporated into the model only for those women who had a pregnancy after a TA. The decision tree model is not shown.
Statistical analysis was based on a data-driven probabilistic decision model. Traditional P values were not included as this cost analysis was based on simulated data and a probabilistic model. Extensive sensitivity analyses have been included to evaluate the robustness of the model and the underlying assumptions.
RESULTS
We evaluated 2,256 TA procedures from the literature. The PRs for TA were 75%, 66%, and 44% for maternal age <35, 35-40, and >40 years, respectively. Ongoing PRs ranged from 5%-63%, with decreasing rates as patient age increased (Table 1) . We evaluated IVF cycles from the 2012 SART data for women with a diagnosis of tubal factor infertility, demonstrating PRs per cycle for fresh cycle IVF of 46%, 35%, and 16% for maternal age <35, 35-40, and >40 years. Evaluation of frozen ET cycles from 2012 SART data showed that the percentage of IVF cycles that had frozen embryos available for a subsequent transfer ranged from 44% in the youngest age group to 33% in the oldest age group ( Table 1) . As expected, the pregnancy percentage and the ongoing pregnancy percentage decreased with increasing age for all procedures and the probability of not having an embryo, fresh or frozen, available for transfer for IVF increased with age.
Using the decision tree analysis (Fig. 1) , the cost per ongoing pregnancy after TA was $16,315, $23,914, and $218,742 for <35-, 35-to 40-, and >40-year-old women, respectively (Table 2 ). For patients undergoing IVF, the cost per ongoing pregnancy was $32,814, $45,839, and $111,445 for <35-, 35-to 40-, and >40-year-old women, respectively ( Table 2 ). The IVF group had a lower estimated cost per ongoing pregnancy only in women >40 years of age. As the probability of pregnancy decreased, the charges for an ongoing pregnancy of both procedures increased across all age groups. Using the costs estimated in the primary model, TA was the most cost effective as long as the ongoing PR was >20%, >15%, and >10% for ages <35, 35-40, and >40 years, respectively (Supplemental Fig. 1, available  online) .
A one-way sensitivity analysis was performed, varying the range of charges for IVF from $3,000 to $50,000, and keeping the charges for the TA constant at $8,685 (the mean charge for a TA). The calculated patient cost for an ongoing pregnancy was equal between the two procedures only when the charges for IVF were $6,500, $7,000, and $30,000 for ages <35, 35-40, and >40 years, respectively, and favored IVF when the charge per IVF cycle decreased below that amount (Fig. 2) . A similar sensitivity analysis was performed keeping the charges of IVF constant at $13,970, and varying the range of charges of TA from $1,000 to $21,000, which indicated that the calculated cost per ongoing pregnancy was equal between the two procedures only when the TA procedure cost $18,000, $17,000, and $4,000 for ages <35, 35-40, and >40 years, respectively, and favored the TA procedure at any charge below that amount (Fig. 2) . For the secondary decision trees incorporating OHSS, HSG, and contraception costs into the model, TA continued to be the more cost-effective method for obtaining an ongoing pregnancy for those women less than 41 years of age (Supplemental Table 3 , available online).
DISCUSSION
Few studies have compared the cost effectiveness of TA versus IVF for patient's desiring fertility after a previous tubal ligation (6, 25) . Our model suggests that for women <41 years of age, TA is the most cost-effective method for achieving an ongoing pregnancy. The sensitivity analyses revealed that TA was more cost effective as long as the cost per IVF cycle was more than or equal to $6,500 or $7,000 for women <35 and 35-40 years of age, respectively, a cost that is significantly lower than reported in the literature or by fertility clinics. In women more than age 40 years, TA became more cost effective if IVF was more than or equal to $30,000 per cycle.
It is well known that age is a major factor affecting PRs and spontaneous abortion rates, for IVF and spontaneous conception. A previous study of pregnancy after TA noted that each increase in age of 5 years decreased the chances of becoming pregnant by up to 38% (7). In the model presented, the probability of an ongoing pregnancy decreased markedly as age increased. For the IVF arm, the spontaneous abortion rate was extrapolated from SART data and was low across all age groups, particularly women more than age 40 years, when compared with the general population (24) . As SART data reflect an ideal patient population and likely is artificially low, a model was run with equivalent spontaneous abortion rates in both TA and IVF arms of 34% for women aged >40 years. In this model, IVF remained more cost effective for women more than 40 years of age (A-C) Sensitivity analysis for each age group in which the cost of a tubal anastomosis (TA) was held constant (median value $8,685) and the charges for IVF were varied from $3,000 to $50,000. (D-F) Sensitivity analysis for each age group in which the cost of IVF was held constant (median value $13,970) and the charges for TA were varied from $1,000 to $21,000. (data not shown). This is consistent with the ASRM practice bulletin that notes age as the most important prognostic factor for TA (4) . Although our analysis may underestimate the TA and IVF costs, the results are consistent with those reported in the literature (6, 25) . The results of our analysis reflect the estimated patient charges obtained from the literature and from clinics that regularly perform tubal reversals and IVF. As only 15 states currently have mandated infertility insurance coverage, not all of which cover IVF, we believe that patient charges are a suitable measure for this model (56) . Charges for TA are not consistent throughout the United States and vary according to the surgical approach. As the majority of clinics are performing TA using the mini-laparotomy approach, we did not stratify cost by method of TA, but included the cost of all methods in calculating the mean and range of charges. A recent cost analysis of robotic versus laparotomy for TA showed the cost to be $1,446 more for robotic procedures (8) , a difference that is accounted for in our sensitivity analysis.
This study evaluated costs with regard to the efficacy of the respective procedures; however, there are other potential costs to consider. For patients undergoing TA who fail to achieve a pregnancy after 6 months, many (up to 45%) will have a HSG. For those going through IVF, OHSS, a rare, but serious complication may occur (50, 51) . Our model is unique in that we analyzed a version of the model that accounted for the additional cost of HSG for 45% of those who completed a TA procedure and OHSS for 2% of IVF patients who completed an ET. Despite these added costs, the outcomes remained the same, with TA being the most cost-effective option for women <41 years of age (Supplemental Table 3 ).
Another consideration is long-term family planning. If successful, a TA would permit several pregnancies from the initial expense, whereas IVF would require additional expenses per attempt. If only one additional child is desired, TA would require subsequent contraception, certainly adding long-term cost to the patient. As this may be a significant financial burden on the patient, a separate model was run that included cost for contraception in those women who have a pregnancy after TA surgery. As there are a number of contraception options with widely varying cost, an average cost was calculated based on the available literature (54, 55) . The cost used in the model is a blended average of all types of contraception-it is a reasonable estimation given the variety of available options. In addition, the sensitivity analysis could be used to adjust for the cost of contraception based on individual patient preference. In this model, the results remained consistent with TA being most cost effective for women <41 years of age (Supplemental Table 3 ).
There may also be differences in time lost from work, costs associated with each procedure. For IVF patients, a total of 5 days per cycle for either one or both partners has been included in the literature (6, 57) , and for patients undergoing TA, ranges of 7-20 days have been documented as time lost for postoperative recovery (6, 8) . These time ranges account only for time away directly related to fertility treatment and do not account for subsequent pregnancy care. Due to the high variability of time missed by each partner, as well as the wide range of wages, we chose not to include this in our analysis. However, sensitivity analyses varying the cost of the procedures showed similar results across a wide range of potential costs.
This study did not consider the differences in pregnancy care and delivery costs. Because IVF is more likely to result in a multiple gestation pregnancy, it is more likely to result in higher charges related to managing and treating medical complications during pregnancy and complications during delivery, including a cesarean delivery. A recent analysis including delivery costs concluded that TA was more cost effective for all age groups when including delivery charges (25) . This analysis focused on cost to obtain an ongoing pregnancy, as for many patients, this was the primary concern.
In addition to cost and efficacy, there are other concerns with each procedure that patients and clinicians may want to consider. The success rates for the TA procedure reflect those reported for the most experienced surgeons with a highly selective patient population. There is limited literature to provide an accurate estimation of how many women desiring fertility after tubal ligation are such optimal candidates. The data used in this model assume that all women desiring this procedure would be ideal candidates. Although the mean time to conception reported is 6.8 months, the overall high success rates may also be associated with a longer time to follow-up. A longer time to conception for TA may be a deterrent for many patients, particularly those at the upper end of the reproductive age spectrum. For some individuals the shorter time to pregnancy afforded by IVF may outweigh any cost benefit.
Strengths of this analysis are several. The study includes all surgical methods of TA, as well as management of known outcomes and complications including EPs, spontaneous abortions, and OHSS. In addition we focused on a single cycle of IVF plus a frozen cycle if indicated. Many finance plans now exist, in addition to insurance coverage in certain areas. Our robust sensitivity analysis allows for inclusion of this coverage, as well as plans that may include multiple cycles with overall improved PRs to better individualize counseling to patients. Important, we provide a decision tree model that can easily be customized to costs and outcomes in a given clinic to guide in patient counseling and decision making. In conclusion, the cost and efficacy of TA versus IVF confirms that TA is the favored approach for many patients under age 41 years desiring fertility after tubal ligation.
